Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03548194
Registration number
NCT03548194
Ethics application status
Date submitted
27/03/2018
Date registered
7/06/2018
Date last updated
9/07/2020
Titles & IDs
Public title
A Study of BNC210 in Elderly Patients With Agitation
Query!
Scientific title
A Phase II Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BNC210 in Hospitalised Elderly Patients With Agitation
Query!
Secondary ID [1]
0
0
BNC210.008
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Agitation in the Elderly
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Anxiety
Query!
Mental Health
0
0
0
0
Query!
Other mental health disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BNC210
Treatment: Drugs - Placebo
Experimental: BNC210 - Administered orally b.i.d. for 5 days.
Placebo comparator: Placebo - Administered orally b.i.d. for 5 days.
Treatment: Drugs: BNC210
BNC210 300 mg b.i.d
Treatment: Drugs: Placebo
Placebo b.i.d.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Absolute change in agitation, as measured by the Pittsburgh Agitation Scale (PAS).
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
5 days
Query!
Secondary outcome [1]
0
0
Absolute change in global function, as measured by the Clinical Global Impression Scale - Severity and Improvement (CGI-S/I)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
5 days
Query!
Secondary outcome [2]
0
0
Proportion of participants reaching the "Non-Agitated" state
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
5 days
Query!
Secondary outcome [3]
0
0
Time to first reach a "Non-Agitated" state.
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
5 days
Query!
Eligibility
Key inclusion criteria
Key
* Male or female elderly patient admitted to hospital and under the care of a specialist Geriatrician
* Determined to have agitation requiring intervention in addition to standard of care behavioural management, as assessed by the Investigator or delegate, after at least 24 hours following admission to hospital.
Key
Query!
Minimum age
No limit
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Severe Alzheimer's Dementia (stage 7) as assessed by the Functional Assessment Staging Test (FAST).
* Diagnosed with Severe Parkinson's Disease.
* Premorbid psychotic illness as assessed by the Investigator.
* Evidence of severe organ dysfunction
* Confirmed metastatic malignancy.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
17/05/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
24/04/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
38
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Prince of Wales Hospital - Sydney
Query!
Recruitment hospital [2]
0
0
Modbury Hospital - Adelaide
Query!
Recruitment hospital [3]
0
0
Northern Health - Melbourne
Query!
Recruitment hospital [4]
0
0
Royal Melbourne Hospital - Melbourne
Query!
Recruitment hospital [5]
0
0
Western Health - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Sydney
Query!
Recruitment postcode(s) [2]
0
0
- Adelaide
Query!
Recruitment postcode(s) [3]
0
0
- Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bionomics Limited
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase II randomised, double-blind, placebo-controlled study assessing the effects of BNC210 on agitation in hospitalised elderly patients as measured by the Pittsburgh Agitation Scale (PAS). Safety and tolerability of BNC210 will also be assessed. The secondary objectives of the study include evaluation of the effects of BNC210 on global function in patients with agitation as assessed by the Clinical Global Impression Scale (CGI-S/I). Participants will receive 5 days of blinded treatment followed by 2 days of follow up.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03548194
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03548194
Download to PDF